About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Francesca DeMartino Chief Investor Relations Officer, Senior Vice President Fourth Quarter 2025 Earnings 2 Fourth Quarter 2025 Earnings Teleconference February 3, 2026 1 Introduction Forward-Looking Statements and Non-GAAP Financial Information Fourth Quarter 2025 Earnings 3 • Our discussions during this conference call will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such s ...

（责任编辑：王治强 HF013） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 每经AI快讯，2月3日，辉瑞股价下跌4%。 每日经济新闻 ...

辉瑞(PFE.N)跌4%，其业绩前景展望和减肥药数据令市场失望。 本文源自：金融界AI电报 ...

分组1 - Pfizer reported quarterly earnings of $0.66 per share, exceeding the Zacks Consensus Estimate of $0.57 per share, and showing an increase from $0.63 per share a year ago, resulting in an earnings surprise of +16.81% [1] - The company achieved revenues of $17.56 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 4.26%, although this represents a decline from year-ago revenues of $17.76 billion [2] - Pfizer has surpassed consensus EPS estimates in all four of the last quarters and has topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has gained approximately 7.1% since the beginning of the year, outperforming the S&P 500, which has gained 1.9% [3] - The future performance of Pfizer's stock will largely depend on management's commentary during the earnings call and the outlook for earnings estimates [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.75 on revenues of $13.9 billion, and for the current fiscal year, it is $2.97 on revenues of $60.81 billion [7] 分组3 - The Large Cap Pharmaceuticals industry, to which Pfizer belongs, is currently ranked in the bottom 23% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - The Zacks Rank for Pfizer is currently 5 (Strong Sell), suggesting that the stock is expected to underperform the market in the near future [6]

On Tuesday, Pfizer Inc. (NYSE:PFE) shared topline data from a mid-stage study for a weight loss drug and reported fourth quarter earnings that beat consensus estimates.Weight Loss DataPfizer released data from the Phase 2b VESPER-3 study of monthly maintenance dosing of PF'3944 (MET-097i) in adults with obesity or overweight without type 2 diabetes.The U.S. drug giant added the ultra-long-acting, injectable GLP-1 receptor agonist via a massive $10 billion Metsera, Inc. deal.The ongoing 64-week study demonst ...

Group 1: Merck & Co. - Merck's Q4 worldwide sales increased by 5% to $16.4 billion, with a full-year revenue exceeding $65 billion, driven primarily by oncology sales [2] - Keytruda, a major oncology drug, saw sales rise by 7% to nearly $32 billion, constituting almost half of Merck's total annual revenue [2] - New therapies are contributing to sales growth, with Winrevair generating $1.4 billion and Capvaxix bringing in just under $800 million in their first year [3] - Merck's guidance for 2026 revenue is around $66 billion, indicating a flat outlook compared to the current year [3] Group 2: Pfizer - Pfizer's full-year 2025 revenue decreased by 2% to approximately $63 billion, but oncology drugs like Padcev and Lorbrena showed growth [4] - Adjusted EPS for Pfizer rose by 4% to $3.22, supported by expanded margins and stable costs [4] - For 2026, Pfizer forecasts revenue between $59.5 billion and $62.5 billion, with adjusted EPS expected to be between $2.80 and $3.00 [5] - Pfizer's management is optimistic about a busy pipeline with around 20 pivotal study starts planned for the year, aiming to restore growth despite ongoing challenges from patent expirations and pricing pressures [5]

Pfizer reported fourth-quarter results that beat expectations, offering a steadier earnings picture as the company moves further away from the Covid-driven revenue surge of recent years. While demand ... ...

财报显示，辉瑞四季度营收175.6亿美元，同比微降约1%，营收下滑主要源于新冠疫苗及新冠口服药 Paxlovid的需求走低：新冠疫苗销售额为23亿美元，虽高于20亿美元的预期，但同比下降三分之 一;Paxlovid销售额仅为2.18亿美元，远低于5.89亿美元的预期，同比暴跌超过三分之二。 智通财经APP获悉，周二，辉瑞(PFE.US)公布了第四季度财报，尽管新冠相关产品需求持续萎缩，但公 司营收与利润仍双双超出市场预期，同时公司重申了2026年的温和指引——该指引在去年12月公布时曾 引发投资者担忧。另外，辉瑞还公布了其新型减肥疗法的初步数据，但披露信息有限。 不过，这一数字高于市场预期的169.5亿美元，原因是辉瑞的多款重磅药物整体表现符合预期：尽管其 明星肺炎疫苗Prevnar面临默沙东(MRK.US)新产品的竞争，但仍实现17亿美元销售额，略高于16亿美元 的预期;抗凝血药Eliquis销售额达20亿美元，心脏病药物Vyndaqel销售额为17亿美元，均符合市场预测。 为对冲新冠产品销售下滑及老牌药物营收萎缩的影响，这家制药巨头正将目光投向管线产品的长期投 资，其中包括以100亿美元收购肥胖症生物科技 ...

专题：聚焦美股2025年第四季度财报 辉瑞于周二公布四季度业绩，公司利润超华尔街预期，业绩增长得益于阿哌沙班、维达全这类经典药物 的需求持续走高。 据伦敦证券交易所集团汇总的数据，经调整后，辉瑞四季度每股收益为 66 美分，高于分析师此前 57 美 分的预期。 责任编辑：郭明煜 专题：聚焦美股2025年第四季度财报 辉瑞于周二公布四季度业绩，公司利润超华尔街预期，业绩增长得益于阿哌沙班、维达全这类经典药物 的需求持续走高。 据伦敦证券交易所集团汇总的数据，经调整后，辉瑞四季度每股收益为 66 美分，高于分析师此前 57 美 分的预期。 责任编辑：郭明煜 ...